FDA rule targets cheap GLP-1 imitations, boosting Novo Nordisk as it prepares key CagriSema data at ADA. Stock down 36% in 12 months, but pipeline progress and regulatory relief offer upside.<\/p>\n
The stars are aligning for Novo Nordisk, but the market is still waiting for the fireworks. A regulatory clampdown on cheap copycat GLP-1s is clearing the competitive landscape just as the Danish pharma giant prepares to unveil a heavy data package at the American Diabetes Association\u2019s annual meeting. For a stock that has shed roughly 36% over the past twelve months and sits more than 44% below its 52-week peak, the convergence of these two catalysts could be decisive.<\/p>\n
The biggest near-term relief comes from Washington. The FDA has circulated a draft rule that would all but end the mass production of compounded GLP-1 analogues by so-called 503A and 503B pharmacies. These imitations had at one point captured nearly 30% of market volume by exploiting shortages of the branded originals. Jefferies now estimates that share has already slipped to around 15% \u2014 and expects a full implementation of the new restrictions by mid-2027. For Novo Nordisk, that means the pricing pressure from \u201ccopycat\u201d operators is fading faster than many had anticipated.<\/p>\n
Jefferies analyst Michael Leuchten nevertheless remains cautious. In a note published on Friday, he affirmed a \u201cHold\u201d rating and a target price of 270 Danish kroner, roughly 10% below the current level. The stock traded at about 38.90 euros on Monday, just under its 100-day moving average, having recovered about 27% from its March trough. The RSI of 48 points to neutral sentiment \u2014 neither oversold nor overheated.<\/p>\n
The company\u2019s pipeline progress is starting to deliver tangible revenue. Oral semaglutide \u2014 the pill version of Wegovy \u2014 secured a positive EU approval recommendation in May. In its first full quarter on the US market, the oral formulation generated around 2.3 billion Danish kroner in sales, comfortably beating analyst expectations. A high-dose injectable Wegovy is also nearing regulatory submission. But the competitive clock is ticking: Eli Lilly\u2019s oral GLP-1, Foundayo, has been on the US market since April 2026.<\/p>\n
Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\n The real firepower will be on display in New Orleans from June 5 to 8. Novo Nordisk is scheduled to present a total of 40 abstracts at the ADA Scientific Sessions. The centerpiece is the Phase 3 REIMAGINE programme for CagriSema \u2014 a combination of the amylin analogue cagrilintide and semaglutide \u2014 with data on blood-glucose control and weight loss in type 2 diabetes patients on various background therapies. A dedicated symposium is set for June 7.<\/p>\n On the same day, the company will host an R&D investor day to discuss the results in detail. That gives the date a dual significance: clinical evidence and capital-markets communication rolled into one. Also on the agenda are Phase 2b results for zenagamtide (formerly Amycretin), a single-molecule GLP-1\/amylin agonist being developed in both oral and subcutaneous formulations. Neither candidate has yet been approved in the US.<\/p>\n Beyond the headline candidates, the 40 abstracts cover semaglutide in cardiovascular, renal and pulmonary indications \u2014 including asthma, sleep apnoea and MASH \u2014 as well as data on the once-weekly insulins Icodec and IcoSema. The broader message is that Novo Nordisk\u2019s GLP-1 franchise extends far beyond weight loss, a crucial narrative given the intensifying pricing headwinds in its home market. In the first quarter of 2026, adjusted US sales fell 11% on a comparable-currency basis.<\/p>\n